Fig. 2: Scenario analyses. All analyses compare the base case, in which the cost per quality-adjusted life-year (QALY) gained with the use of a sirolimus-eluting stent rather than a conventional stent with PCI is Can$58 721. Each horizontal bar represents the cost per QALY gained in the described scenario, in which 1 or more input values is varied. For example, if the baseline restenosis rate is changed to the RAVEL (RAndomized study with the sirolimus-eluting VELocity balloon-expandable stent⁴) restenosis rate, the cost per QALY decreases to $54 176. *Varying estimates of 7-day mortality and clinical-event rates in patients in the cohort of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH). SIRIUS = study of the SIRolImUS-eluting stent,⁵ HRQOL = health-related quality of life.